Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan 10;9(1):e00735.
doi: 10.14309/crj.0000000000000735. eCollection 2022 Jan.

Olaparib-Induced Immune-Mediated Liver Injury

Mohammad Alshelleh  1 , Jennifer Park  2 , Veena John  2 , Arvind Rishi  3 , David Bernstein  4 , Nitzan Roth  4
Affiliations
Case Reports

Olaparib-Induced Immune-Mediated Liver Injury

Mohammad Alshelleh et al. ACG Case Rep J. .

Abstract

Immune-mediated drug-induced liver injury can be triggered by multiple classes of medications including immunotherapies. Olaparib is a first-in-class oral inhibitor of poly (adenosine diphosphate-ribose) polymerase (an enzyme involved in DNA replication and repair) that is approved as maintenance treatment in platinum-sensitive, epithelial ovarian, tubal, or primary peritoneal cancers with breast cancer 1/2 mutation. We report the first case in the United States of an acute and severe liver injury with associated jaundice and liver synthetic dysfunction secondary to olaparib. The liver injury was resolved with drug cessation and treatment with prednisone taper.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Ductular proliferation with acute cholangitis (between 2 arrows).
Figure 2.
Figure 2.
Areas of submassive necrosis with lobular collapse. Note that no viable hepatocytes are identified.
Figure 3.
Figure 3.
Graph of liver enzymes.
See this image and copyright information in PMC

References

    1. Tew WP, Lacchetti C, Ellis A, et al. . PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol 2020;38(30):3468–93. - PMC - PubMed
    1. de Bono J, Mateo J, Fizazi K, et al. . Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020;382(22):2091–102. - PubMed
    1. Golan T, Hammel P, Reni M, et al. . Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381(4):317–27. - PMC - PubMed
    1. Robson M, Im SA, Senkus E, et al. . Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377(6):523–33. Erratum in: N Engl J Med 2017;377(17):1700. - PubMed
    1. Ledermann J, Harter P, Gourley C, et al. . Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15(8):852–61. Erratum in: Lancet Oncol 2015;16(4):e158. - PubMed

Publication types